|
|
|
International Clinical Trials
|
It’s a relatively calm and quiet Friday afternoon, until you hear it, the chime of a new email coming through your speakers. “Urgent: Class II recall of Molecule RFGH79245 – Lot XFD157899,” the subject line reads. Now, in just a moment’s time, what was once a quiet office environment has turned into a cacophony of conversations regarding vendor processes, systems, who has the latest Excel tracker, and more.
Regrettably, this is the scene of several pharmaceutical companies, moments after receiving a lot recall notice for a clinical trial. In fact, many organisations in trials lag behind their commercial counterparts in terms of trial supply sophistication and visibility. While manual systems and processes can work, they often present serious hurdles for those looking to accurately forecast, predict, and solve clinical trial supply issues. As the introduction illustrates, manual processes can quickly become an administrative nightmare any time there’s a serious bump in the road.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
About the author
The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, patient engagement, interactive response technology, clinical supplies, and endpoint quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise, and global operational scale enable hundreds of sponsors and CROs (including all top 20 pharma) to extend the reach of drug development, expand patient opportunities, and improve data quality – helping them bring lifechanging therapies to our families and communities around the world.
hello@signanthealth.com
www.signanthealth.com
|
|
|
|
|
|
 |
News and Press Releases |
 |
WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System
Shanghai, China, 5 April 2023: WuXi STA,
a global Contract Research, Development, and Manufacturing Organization
(CRDMO), announces that it has added two 2,000 L reactors and a
large-scale continuous purification system for peptide manufacturing at
its Changzhou campus.
More info >> |
|
 |
White Papers |
 |
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
RSSL
Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >> |
|
|
